Malignant Hyperthermia ACT SheetAimer: This guideline is designed primarily as an educational resource for clinicians to help them provide quality medical care It should

ORIGINAL ARTICLE Central core disease: clinical, pathological, and genetic features R M Quinlivan, C R Muller, M Davis, N G Laing, G A Evans, J Dwyer, J Dove, A P Roberts,

217th ENMC International Workshop: RYR1-related Myopathies, 29-31st January 2016, Naarden, The NetherlandsJanuary 2016, Naarden, The Netherlands Author: Heinz Jungbluth,

1 Clincal Care Guidelines Clinical Care Guidelines WHAT PATIENTS & FAMILIES NEED TO KNOW ABOUT RYR-1-RELATED DISEASES 2 Clinical Care Guidelines Disclaimer, please read:

Received: November 23, 2020 Accepted: November 23, 2020 Correspondence Mariz Vainzof Human Genome and Stem Cell Research Center, IBUSP, Rua do Matão 106, Cidade Universitária,

ORTHO1109Stratman.indd pharmacology update Malignant hyperthermia is a rare, life-threat- ening, autosomal-dominant, pharmacogenetic, anesthetic- related disorder that occurs

Pre-operative exercise and pyrexia as modifying factors in malignant hyperthermia (MH)Contents lists available at ScienceDirect Neuromuscular Disorders hyperthermia (MH)

PDF hosted at the Radboud Repository of the Radboud University Nijmegen For additional information about this publication click this link. https://hdl.handle.net/2066/229439